Sotera Health (NASDAQ:SHC) Shares Sold by Barclays PLC

Barclays PLC decreased its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 68.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,731 shares of the company's stock after selling 323,866 shares during the quarter. Barclays PLC owned about 0.05% of Sotera Health worth $2,050,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SHC. Blue Trust Inc. boosted its position in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after purchasing an additional 1,140 shares during the period. GAMMA Investing LLC boosted its position in shares of Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock worth $56,000 after buying an additional 1,121 shares during the period. Sterling Capital Management LLC grew its stake in shares of Sotera Health by 58.5% in the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company's stock valued at $124,000 after buying an additional 3,331 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Sotera Health by 39.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,302 shares of the company's stock valued at $127,000 after buying an additional 2,627 shares during the period. Finally, Optimize Financial Inc acquired a new position in Sotera Health during the 4th quarter worth about $185,000. Institutional investors and hedge funds own 91.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SHC. Barclays dropped their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Piper Sandler dropped their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $15.20.

Sotera Health Trading Up 5.2 %

NASDAQ SHC opened at $12.10 on Friday. Sotera Health has a 52 week low of $9.53 and a 52 week high of $17.08. The firm has a 50 day moving average of $11.40 and a two-hundred day moving average of $13.07. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The stock has a market capitalization of $3.43 billion, a PE ratio of 48.40 and a beta of 1.88.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.